Preclinical Evaluation of F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors

Overview

Journal Mol Imaging

Publisher Sage Publications

Specialty Radiology

Date 2017 Jun 28

PMID 28654376

Citations 5

Authors

Emre Demirci

Rafay Ahmed

Meltem Ocak

Joseph Latoche

April Radelet

Nicole DeBlasio

N Scott Mason

Carolyn J Anderson

James M Mountz

Affiliations

Soon will be listed here.

Abstract

Purpose: We investigated 2-(5-fluoro-pentyl)-2-methyl-malonic acid (F-ML-10) positron emission tomography (PET) imaging of apoptosis posttherapy to determine optimal timing for predicting chemotherapy response in a mouse head/neck xenograft cancer model.

Procedures: BALB/c nude mice (4-8 weeks old) were implanted with UM-SCC-22B tumors. The treatment group received 2 doses of doxorubicin (10 mg/kg, days 0, 2). Small animal F-ML-10 PET/computed tomography was performed before and on days 1, 3, and 7 postchemotherapy. Using regions of interest around tumors, F-ML-10 uptake change was measured as %ID/g and uptake relative to liver. Terminal Uridine Nick-End Labeling (TUNEL) immunohistochemistry assay was performed using tumor samples of baseline and on days 1, 3, and 7 posttreatment.

Results: Treated mice demonstrated increased F-ML-10 uptake compared to baseline and controls, and 10 of 13 mice showed tumor volume decreases. All control mice showed tumor volume increases. Tumor-to-liver (T/L) ratios from the control group mice did not show significant change from baseline ( P > .05); however, T/L ratios of the treatment group showed significant F-ML-10 uptake differences from baseline compared to days 3 and 7 posttreatment ( P < .05), but no significant difference at 1 day posttreatment.

Conclusion: 2-(5-Fluoro-pentyl)-2-methyl-malonic acid PET imaging has the potential for early assessment of treatment-induced apoptosis. Timing and image analysis strategies may require optimization, depending on the type of tumor and cancer treatment.

Citing Articles

The therapeutic effect of a novel GAPDH inhibitor in mouse model of breast cancer and efficacy monitoring by molecular imaging.

Zhang Y, Zhang W, Kong X, Hai W, Guo R, Zhang M Cancer Cell Int. 2024; 24(1):188.

PMID: 38811918 PMC: 11138053. DOI: 10.1186/s12935-024-03361-x.

Interest and Limits of [F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy.

Jouberton E, Schmitt S, Maisonial-Besset A, Chautard E, Penault-Llorca F, Cachin F Front Oncol. 2022; 11:789769.

PMID: 34988022 PMC: 8722713. DOI: 10.3389/fonc.2021.789769.

Apoptosis Imaging in Oncology by Means of Positron Emission Tomography: A Review.

Van de Wiele C, Ustmert S, De Spiegeleer B, De Jonghe P, Sathekge M, Alex M Int J Mol Sci. 2021; 22(5).

PMID: 33803180 PMC: 7963162. DOI: 10.3390/ijms22052753.

[F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer.

Jouberton E, Schmitt S, Chautard E, Maisonial-Besset A, Roy M, Radosevic-Robin N EJNMMI Res. 2020; 10(1):2.

PMID: 31907640 PMC: 6944726. DOI: 10.1186/s13550-019-0587-5.

Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.

Vassileva V, Stribbling S, Barnes C, Carroll L, Braga M, Abrahams J EJNMMI Res. 2019; 9(1):18.

PMID: 30783791 PMC: 6381199. DOI: 10.1186/s13550-019-0487-8.

References

Blankenberg F . In vivo detection of apoptosis. J Nucl Med. 2008; 49 Suppl 2:81S-95S. DOI: 10.2967/jnumed.107.045898. View

Yang T, Haimovitz-Friedman A, Verheij M . Anticancer therapy and apoptosis imaging. Exp Oncol. 2012; 34(3):269-76. View

Bao X, Yang Z, Wang S, Zheng Y, Wang M, Gu B . The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging. Oncotarget. 2016; 7(15):20743-52. PMC: 4991489. DOI: 10.18632/oncotarget.7868. View

Meiler J, Schuler M . Therapeutic targeting of apoptotic pathways in cancer. Curr Drug Targets. 2006; 7(10):1361-9. DOI: 10.2174/138945006778559175. View

Witney T, Hoehne A, Reeves R, Ilovich O, Namavari M, Shen B . A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment. Clin Cancer Res. 2015; 21(17):3896-905. PMC: 4558304. DOI: 10.1158/1078-0432.CCR-14-3176. View

Oborski M, Laymon C, Qian Y, Lieberman F, Nelson A, Mountz J . Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10. Transl Oncol. 2014; 7(1):111-9. PMC: 3998694. DOI: 10.1593/tlo.13868. View

Zhang F, Zhu L, Liu G, Hida N, Lu G, Eden H . Multimodality imaging of tumor response to doxil. Theranostics. 2011; 1:302-9. PMC: 3139195. DOI: 10.7150/thno/v01p0302. View

Zhu X, Li Z, Zhao M . Imaging acute cardiac cell death: temporal and spatial distribution of 99mTc-labeled C2A in the area at risk after myocardial ischemia and reperfusion. J Nucl Med. 2007; 48(6):1031-6. DOI: 10.2967/jnumed.106.037754. View

KERR J, Wyllie A, Currie A . Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26(4):239-57. PMC: 2008650. DOI: 10.1038/bjc.1972.33. View

10.

Vermeersch H, Loose D, Lahorte C, Mervillie K, Dierckx R, Steinmetz N . 99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma. Nucl Med Commun. 2004; 25(3):259-63. DOI: 10.1097/00006231-200403000-00008. View

11.

Bauwens M, De Saint-Hubert M, Devos E, Deckers N, Reutelingsperger C, Mortelmans L . Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol. 2011; 38(3):381-92. DOI: 10.1016/j.nucmedbio.2010.09.008. View

12.

Su H, Chen G, Gangadharmath U, Gomez L, Liang Q, Mu F . Evaluation of [(18)F]-CP18 as a PET imaging tracer for apoptosis. Mol Imaging Biol. 2013; 15(6):739-47. DOI: 10.1007/s11307-013-0644-9. View

13.

Johansen P . Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol. 1981; 5(4):267-70. DOI: 10.1007/BF00434396. View

14.

Allen A, Ben-Ami M, Reshef A, Steinmetz A, Kundel Y, Inbar E . Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with ¹⁸F-ML-10. Eur J Nucl Med Mol Imaging. 2012; 39(9):1400-8. DOI: 10.1007/s00259-012-2150-8. View

15.

Wang J, Zheng W, Liu J, Chen Y, Cao L, Luo R . Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts. PLoS One. 2013; 8(3):e58274. PMC: 3585723. DOI: 10.1371/journal.pone.0058274. View

16.

Bauwens M . In Vivo Apoptosis Imaging Using Site-Specifically (68)Ga-Labeled Annexin V. Methods Mol Biol. 2016; 1419:17-26. DOI: 10.1007/978-1-4939-3581-9_2. View

17.

Kaufmann S, Earnshaw W . Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000; 256(1):42-9. DOI: 10.1006/excr.2000.4838. View

18.

Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, van Oers M . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84(5):1415-20. View

19.

Kadirvel M, Fairclough M, Cawthorne C, Rowling E, Babur M, McMahon A . Detection of apoptosis by PET/CT with the diethyl ester of [¹⁸F]ML-10 and fluorescence imaging with a dansyl analogue. Bioorg Med Chem. 2013; 22(1):341-9. DOI: 10.1016/j.bmc.2013.11.019. View

20.

Hoglund J, Shirvan A, Antoni G, Gustavsson S, Langstrom B, Ringheim A . 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011; 52(5):720-5. DOI: 10.2967/jnumed.110.081786. View